Tymlos (Abaloparatide): EMA vs FDA Approval, Label Differences, and What It Means for You

What Is Tymlos and Why Does Regulatory Framing Matter for Women?

Tymlos is a synthetic analog of parathyroid hormone-related protein (PTHrP). It works differently from anti-resorptive drugs like bisphosphonates: rather than slowing bone breakdown, it directly stimulates new bone formation. For postmenopausal women whose estrogen loss has accelerated cortical and trabecular bone loss, that anabolic mechanism matters.

Regulatory framing matters because the label you read in your pharmacy bag is not identical worldwide. The FDA label and the EMA-approved SmPC (Summary of Product Characteristics) for Eladynos differ on duration of use, cardiovascular signal language, and the populations studied. If you see information about this drug from a European source, the recommendations may not map exactly onto US prescribing.

Both agencies reviewed the same core key dataset, the ACTIVE trial, yet reached modestly different conclusions about how long you should stay on the drug and what warnings deserve the most prominent placement. That difference is worth understanding before you and your clinician decide whether abaloparatide belongs in your fracture-prevention plan.

FDA Approval: What the Tymlos Label Actually Says

Approval Date and Indication

The FDA approved Tymlos on April 28, 2017, making it the second anabolic agent for osteoporosis after teriparatide (Forteo). The approved indication is treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance to other osteoporosis therapies.

Dose and Administration

The FDA label specifies 80 mcg injected subcutaneously once daily into the periumbilical abdomen. Duration is capped at 24 months (2 years) over a lifetime. After completing a course of abaloparatide, the label recommends transitioning to an anti-resorptive agent to maintain bone mineral density gains. Skipping that sequential step means much of the BMD gain is lost within 12 months.

Black Box Warning: Osteosarcoma

The most prominent safety signal on the FDA label is a Black Box Warning for osteosarcoma. Rat studies showed a dose- and duration-dependent increase in osteosarcoma at exposures greater than those used clinically. No causal link to human osteosarcoma has been established in post-market surveillance, but the FDA chose maximum caution given the class precedent set by teriparatide.

Because of this warning, Tymlos carries absolute contraindications for:

• Patients at increased baseline risk for osteosarcoma (Paget disease of bone, prior radiation to bone, open epiphyses, or a prior history of bone malignancy)
• Children and adolescents with open growth plates
• Patients who have received prior teriparatide or abaloparatide for cumulative lifetime 2 years

Cardiovascular and Hypercalcemia Signals

The FDA label notes that orthostatic hypotension occurred in 22% of patients in the ACTIVE trial within 4 hours of injection, compared with 17% on placebo. Women are instructed to inject sitting or lying down initially and to monitor for dizziness. Hypercalcemia and hypercalciuria also appeared, though rates were low; serum calcium monitoring is recommended in women with pre-existing hypercalcemia risk.

FDA's Cardiovascular Signal Language Compared to EMA

The FDA label acknowledges a numerical imbalance in cardiovascular adverse events from ACTIVE but does not include a standalone cardiovascular warning, citing that the differences were not statistically significant in the trial population of 2,463 postmenopausal women. The EMA SmPC, as discussed below, handles this signal with slightly more cautious language.

EMA Approval: How Eladynos Differs From Tymlos

Approval Timeline and Brand Name

The EMA's Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for abaloparatide under the brand name Eladynos in spring 2022, with formal European Commission approval following in June 2022. The five-year delay relative to the FDA reflects both the EMA's independent review timeline and questions the CHMP raised about cardiovascular data completeness during earlier submissions.

Narrower Duration of Use

This is the most clinically relevant label difference. The EMA SmPC limits treatment to 18 months (compared to FDA's 24 months). The CHMP concluded that data supporting benefit-risk beyond 18 months were insufficient, given the osteosarcoma rat signal and the absence of long-term human fracture-outcome data past the ACTIVE trial's 18-month treatment period.

For women in the EU, this means a shorter anabolic window before transitioning to sequential anti-resorptive therapy. Some European clinicians view this as more conservative than necessary; others see it as appropriate caution given the paucity of data in humans beyond 18 months.

EMA's Handling of Cardiovascular Signals

The EMA SmPC includes more explicit language about cardiovascular risk. The CHMP noted a numerical imbalance in atrial fibrillation events during the ACTIVE trial and required post-marketing cardiovascular surveillance as a condition of approval. The EMA label specifies caution in women with a history of cardiac arrhythmia, and this language goes beyond what appears in the FDA Tymlos prescribing information.

For postmenopausal women who already carry elevated cardiovascular risk after estrogen loss, this difference matters. A 60-year-old woman with borderline QT prolongation or a history of paroxysmal AF should have a specific conversation with her clinician about whether the EMA's additional cautionary language is relevant to her case, even if she is prescribed the US version of the drug.

Osteosarcoma Warning: Same Signal, Different Format

Both agencies warn about osteosarcoma, but the format differs. The FDA uses a Black Box Warning, the most severe label format in the US system. The EMA uses a prominent Special Warning in section 4.4 of the SmPC. Substantively, both describe the same rat data and both stop short of asserting proven human causation. The EMA additionally cross-references pharmacovigilance plans and requires periodic safety update reports (PSURs) on a defined schedule as part of the risk management plan.

The ACTIVE Trial: The Evidence Both Agencies Relied On

The ACTIVE trial (Miller et al., JAMA 2016) was a double-blind, randomized controlled trial enrolling 2,463 postmenopausal women with osteoporosis across 10 countries. Women were randomized to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo for 18 months.

Key results:

| Outcome | Abaloparatide | Teriparatide | Placebo | |---|---|---|---| | New vertebral fracture | 0.58% | 0.84% | 4.22% | | Non-vertebral fracture | 2.7% | 3.3% | 4.7% | | Total hip BMD gain | +3.4% | +1.6% | baseline | | Wrist (distal radius) fracture | 0.9% | 1.4% | 1.6% |

The 25% relative risk reduction in major osteoporotic fractures compared to placebo was the primary efficacy anchor for both regulatory dossiers. Abaloparatide showed a numerically lower rate of hypercalcemia than teriparatide (3.4% vs 6.4%), which became a differentiating talking point in both labels.

One limitation both agencies acknowledged: ACTIVE enrolled women aged 49 to 86, with a mean age of 69. Women in early perimenopause or the first decade post-menopause were underrepresented. The fracture data most robustly applies to women aged 65 and older with established osteoporosis, not women who are perimenopausal with osteopenia.

The WomanRx Life-Stage Framework for anabolic osteoporosis therapy:

• Perimenopause (still cycling or <12 months amenorrhea): Abaloparatide is not studied or approved. Bone loss during perimenopause is real, accelerating up to 3% per year, but the appropriate intervention at this stage is typically hormone therapy, weight-bearing exercise, and calcium/vitamin D optimization rather than anabolic agents.
• Early postmenopause (<5 years post-LMP, no fracture history): Anti-resorptive agents (bisphosphonates, denosumab) are usually first-line. Abaloparatide is reserved for high-fracture-risk women.
• Established postmenopause with high fracture risk or prior fragility fracture: This is where abaloparatide's approval lives. The ACTIVE trial population best represents women 65 and older with a T-score of <-2.5 at lumbar spine or total hip, or a prior vertebral fracture.
• Post-abaloparatide: Sequential anti-resorptive therapy is not optional. Studies like ACTIVExtend showed that women who transitioned to alendronate after 18 months of abaloparatide maintained and further increased BMD gains over 24 additional months.

Pregnancy, Lactation, and Contraception: A Required Conversation

Abaloparatide is contraindicated in pregnancy. This is explicit in both the FDA label and the EMA SmPC.

Animal Reproduction Data

Rat and rabbit studies showed skeletal malformations and fetal loss at doses below the human clinical dose on a body-surface-area basis. There are no adequate human pregnancy data. Because the drug's mechanism involves direct effects on osteoblast and osteoclast activity, fetal skeletal development is a theoretical target.

What This Means Practically

The FDA-approved indication is limited to postmenopausal women, meaning women who are no longer having menstrual cycles and are not expected to become pregnant. However, early postmenopausal women are sometimes not far from their last menstrual period, and spontaneous conception, while rare, is not zero in the first 1 to 2 years after amenorrhea begins.

Any woman who has not confirmed menopause (defined as 12 consecutive months without a period without other medical cause) should use reliable contraception during abaloparatide therapy. This is the same principle applied to other drugs that carry teratogenic risk and are prescribed to women who could theoretically conceive.

Lactation

There are no data on abaloparatide transfer into human breast milk. Animal studies suggest secretion into milk. Given that abaloparatide is approved only in postmenopausal women, lactation is not a clinically anticipated scenario. If an unusual case arises involving a premenopausal woman being considered for off-label use, the drug should not be used during breastfeeding.

Pregnancy Reporting

The FDA maintains a pregnancy exposure registry. If a woman inadvertently becomes pregnant while on Tymlos, exposure should be reported to Radius Health at 1-888-RADIUS1. Both the FDA label and EMA SmPC request this reporting to build the human safety database.

Who Is Tymlos Right For (and Not Right For): A Life-Stage View

Right for You If:

• You are postmenopausal with a BMD T-score of <-2.5 at the spine or hip, or you have had a prior fragility fracture
• You have failed, are intolerant of, or have contraindications to bisphosphonates (such as severe renal impairment, GI intolerance, or atypical femoral fracture on prior bisphosphonate)
• Your fracture risk is classified as "very high" by FRAX or by NOGG guidelines (major osteoporotic fracture 10-year probability >20%)
• You can commit to daily self-injection and afford the out-of-pocket cost if insurance coverage is limited

Not Right for You If:

• You are premenopausal (the drug is not approved and not adequately studied in this group)
• You have open epiphyses, Paget disease of bone, unexplained alkaline phosphatase elevation, or a history of bone radiation or skeletal malignancy
• You have already completed a cumulative 2-year lifetime course of abaloparatide or teriparatide
• You have known or suspected pregnancy
• You have severe hypercalcemia

PCOS and Bone Health: A Note

Women with PCOS who have been on hormonal suppression therapy or who have a history of hypothalamic amenorrhea may develop low BMD before menopause. Abaloparatide is not approved for premenopausal bone loss. If you have PCOS-related low BMD, the appropriate workup and management differs from postmenopausal osteoporosis, and the ACOG and Endocrine Society guidelines do not support off-label use of anabolic agents in this group outside of specialist clinical settings.

Post-Market Surveillance: What Has Emerged Since Approval

FDA Sentinel and FAERS Data

Since 2017, the FDA's Sentinel System has monitored real-world abaloparatide safety. Post-market FAERS data have not identified any confirmed human osteosarcoma cases attributed to abaloparatide as of the most recent FDA review cycle. This is reassuring but not definitive: osteosarcoma has a long latency and the drug has been in use for fewer than 10 years in a limited population.

Orthostatic hypotension adverse event reports have been consistent with the ACTIVE trial rate. Injection-site reactions (erythema, edema, pain) remain among the most commonly reported events in FAERS.

EMA Pharmacovigilance

The EMA requires periodic safety update reports for Eladynos as a condition of the 2022 approval. The EMA EPAR for Eladynos is publicly accessible and updated as new PSURs are submitted. No major new safety signals have been added to the SmPC since launch in EU markets.

Real-World Persistence Data

Real-world persistence with daily injectable osteoporosis therapies is lower than in clinical trials. A 2019 observational study in Medicare beneficiaries found that fewer than 40% of women initiating teriparatide (the closest comparator) were still on therapy at 12 months. Abaloparatide adherence data are more limited given its shorter market history, but similar injection-fatigue barriers likely apply. This matters because fracture reduction requires sustained use through the approved treatment duration.

Comparing Abaloparatide to Teriparatide: The Key Differences Women Ask About

Both drugs are anabolic PTH-axis agents, and clinicians sometimes ask which to choose. The ACTIVE trial provided the most direct head-to-head data available.

Hypercalcemia Rate

Abaloparatide produced a lower rate of hypercalcemia than teriparatide in ACTIVE (3.4% vs 6.4%). For women with borderline high-normal calcium, a history of kidney stones, or concurrent vitamin D supplementation at high doses, this difference may tip the decision toward abaloparatide.

Wrist Fracture Reduction

Abaloparatide showed a statistically significant reduction in wrist (distal radius) fractures, while teriparatide did not reach significance for this endpoint in ACTIVE. Wrist fractures are among the most common osteoporotic fractures in postmenopausal women and carry significant functional impact.

Cost and Access

Teriparatide lost patent exclusivity and biosimilar versions (Forteo biosimilars) are now available in some markets, reducing cost. Abaloparatide remains branded as Tymlos in the US with higher out-of-pocket exposure for women without adequate prescription drug coverage. This is a real-world equity issue that clinicians and women should discuss explicitly.

A Note on Evidence Gaps in Women's Research

Women have historically been underrepresented in early-phase drug trials, but osteoporosis is one area where the key trials enrolled women almost exclusively, because postmenopausal osteoporosis is predominantly a women's disease. The ACTIVE trial was 100% female in its study population.

Where the evidence gap exists for abaloparatide is different: younger women (under 55), premenopausal women with low BMD from conditions like PCOS or hypothalamic amenorrhea, and women with primary ovarian insufficiency (POI) are essentially unstudied. The drug's effects on bone in women with POI, who have very low estrogen for decades before the typical menopause age, are unknown. Off-label use in these groups is not supported by data, and clinicians considering it should understand they are working without regulatory guidance.

"The ACTIVE trial gives us high-quality fracture data for older postmenopausal women, but we genuinely do not know how abaloparatide performs or what risks it carries in a 38-year-old with POI or surgical menopause. That is not a regulatory gap we should fill by extrapolation alone." (Elena Vasquez, MD, WomanRx Editorial Board)

Practical Steps Before Starting Tymlos

1. Confirm your DEXA T-score and fracture history meet the high-risk threshold for anabolic therapy.
2. Review your cardiovascular history with your clinician, especially if you have a history of arrhythmia, given the EMA's more explicit cardiovascular language.
3. Obtain baseline serum calcium and consider 24-hour urine calcium if you have kidney stone history.
4. Confirm you are postmenopausal (12 consecutive months without a period not attributable to another cause).
5. Identify your sequential anti-resorptive plan before you start, because the transition is not optional. ACTIVExtend data show BMD gains are preserved with alendronate 70 mg weekly as sequential therapy.
6. Understand the maximum duration: 24 months per FDA, 18 months per EMA. If you are in the US, the 24-month limit applies to your label; if your clinician is referencing European guidelines, the 18-month limit may be the frame of reference.
7. Confirm you do not have any of the osteosarcoma-risk contraindications listed in the Black Box Warning before your first dose.